In the review, the expert panel notes that while there is robust evidence supporting the association between LDL-cholesterol levels and cardiovascular disease, the association between triglyceride levels and cardiovascular disease is more uncertain.
The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).
FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
While the shrimp diet did increase people's so-called bad cholesterol or LDL slightly, it also boosted their so-called good cholesterol or HDL enough to offset the increase in bad cholesterol.
Cholesterol is clearly not the only risk factor for cardiovascular disease -- half of all heart attacks occur in people with normal levels of LDL, or bad cholesterol -- but the accuracy of CRP as a predictor of cardiac risk has been disputed.
CNN: FDA considers statin use for those with normal cholesterol
In December 2012, the FDA approved Juxtapid (lomitapide) to reduce LDL-C, total cholesterol, apolipoprotein B, and non HDL-C in patients with HoFH.
FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
Regular intake of soy protein and the omega-3 fatty acids in tofu, can reduce cholesterol levels by as much as 30% and LDL (bad cholesterol) by 30%-40%.
Low-density lipoprotein (LDL) or bad cholesterol levels should be below 100, and high-density lipoprotein (HDL) should measure 35 or above.
However, Vascepa has a key advantage over Lovaza, which can raise LDL, or so-called bad cholesterol.
These studies had led to new cholesterol guidelines in the U.S. that suggested lowering low-density lipoprotein (LDL), or bad cholesterol, to extemely low levels.
Clinton's LDL, or so-called "bad cholesterol" level, was 177 and jumped 40 points in the last year of his presidency.
Takeda's pill, TAK-475, aimed to lower LDL cholesterol in a different way than either the statins or Zetia.
The medicine worked incredibly well, lowering low-density lipoprotein (LDL), the bad cholesterol, by 70%.
FORBES: How A Mourning Entrepreneur And A Dogged Doctor Rescued A Rare Disease Drug
"Bad" cholesterol - low density lipoproteins (LDL) - contribute to furring of the arteries.
"I'm confused, " he says, because reducing low-density lipoprotein (LDL), or bad cholesterol, is such a cornerstone of cardiology.
Both work by inhibiting an obscure molecule called the cholesterol ester transfer protein (CETP) that works indirectly to prevent HDL from being used to create low-density lipoprotein (LDL), the bad cholesterol.
Zetia (generically known as ezetimibe) lowers low-density lipoprotein (LDL), the bad cholesterol involved in causing heart attacks and strokes, but less so than existing drugs like Lipitor (generically known as atorvastatin), Crestor, from AstraZeneca, or simvastatin.
FORBES: Merck's Cholesterol Pill Win Is Already Drawing Fire
Because LDL cholesterol is a major risk factor for heart disease, it's the main focus of cholesterol-lowering treatment.
But when Zetia was combined with a statin like Lipitor or Zocor, it lowered bad cholesterol, or low-density lipoprotein (LDL), more than anything else out there.
These post-menopausal women had somewhat high LDL ("bad" cholesterol), but they were otherwise healthy, with an average age of 56 (that's young) and an average HDL ("good" cholesterol) of 67 (that's high).
Schering and Merck have defended the drugs by pointing to the mountains of evidence that support the idea that lowering low-density lipoprotein, commonly known as LDL or "bad cholesterol, " prevents heart attacks.
Most of the time low-density lipoprotein (LDL), better known as "bad cholesterol, " sits around doing little.
For patients at the highest risk of heart attack, the new guidelines suggest that "bad cholesterol, " or low-density lipoprotein (LDL), be reduced to 70 mg per deciliter--although the new guideline is optional.
Daniel Rader of the University of Pennsylvania, one of the world's top experts on the science of cholesterol, says a laser-like focus on LDL-lowering has been one reason deaths from cardiovascular disease are dropping.
Better yet, it cut LDL, the bad cholesterol, by 18% more than Lipitor alone--a substantial decrease.
Up until now, evidence for statins has been mainly in people with high "bad" cholesterol, properly known as low-density lipoprotein (LDL).
"The system is set up so that the HDL high density lipoproteins, or artery-cleaning or 'good' cholesterol, cleans out the LDL low density lipoproteins, or 'bad' cholesterol, " she explains.
Whereas LDL brings cholesterol to the artery wall, where it collects in heart attack-causing plaques, HDL carts it away.
Like many others, I am looking forward to seeing the final IMPROVE-IT results as it will add to our basic understanding of LDL cholesterol and heart disease treatments.
FORBES: Cholesterol Drug Heart Study Continues, But Will Merck's Vytorin Really IMPROVE-IT?
Furthermore, landmark studies such as the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) and the Scandanavian Simvastatin Survival Study (4S) showed that lowering LDL cholesterol has the direct result of reducing cardiovascular (CV) deaths.
FORBES: Do We Really Need Head-To-Head Comparison Trials With Statins To Improve Cardiac Health?
应用推荐